[
    [
        {
            "time": "2018-03-15",
            "original_text": "Benzinga's Bulls & Bears Of The Week: AbbVie, Lululemon, Netflix, Snap And More",
            "features": {
                "keywords": [
                    "Bulls",
                    "Bears",
                    "AbbVie",
                    "Lululemon",
                    "Netflix",
                    "Snap"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "retail",
                    "entertainment",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Benzinga's Bulls & Bears Of The Week: AbbVie, Lululemon, Netflix, Snap And More",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Phase 2 IMBRUVICA速 (ibrutinib) Plus VENCLEXTA速 (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)",
            "features": {
                "keywords": [
                    "IMBRUVICA",
                    "VENCLEXTA",
                    "Phase 2",
                    "Chronic Lymphocytic Leukemia",
                    "high rates",
                    "responses"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Phase 2 IMBRUVICA速 (ibrutinib) Plus VENCLEXTA速 (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]